Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 7/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.79 |
| ▸ | CDK9 | P50750 | 12/20 | 0.73 |
| ▸ | CDK7 | P50613 | 4/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.73 |
| ▸ | CCNH | P51946 | 3/20 | 0.73 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.73 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26399636 | 0.92 | CDK2 (0.85) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL26128863 | 0.91 | CDK2 (0.84) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL6906730 | 0.91 | CDK2 (0.84) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL24758393 | 0.91 | CDK2 (0.83) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL20905302 | 0.91 | CDK2 (1.00) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL14067130 | 0.91 | HDAC3 (0.89) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL26129922 | 0.90 | CDK2 (0.81) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL19475808 | 0.89 | CDK2 (0.81) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL21680378 | 0.89 | HDAC3 (0.82) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL20897371 | 0.89 | HDAC3 (0.86) | CDK2CCNE2CCNE1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188524-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-08-07 | — | — | US | claimed |
| WO-2008049856-A2 | METHODS OF TREATING PAIN USING CDK INHIBITORS | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-05-02 | — | — | WO | claimed |
| EP-1568368-A1 | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-31 | — | — | EP | claimed |
| EP-1240166-B1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1429764-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | claimed |
| US-20030114504-A1 | Compositions and methods for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | claimed |
| US-6534531-B2 | Thiazole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-18 | — | — | US | claimed |
| WO-2003020272-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| US-6515004-B1 | Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | claimed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | claimed |
| US-20080188524-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-08-07 | — | — | US | disclosed |
| EP-1568368-A1 | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1240166-B1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1303513-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6534531-B2 | Thiazole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-18 | — | — | US | disclosed |
| EP-1240166-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2002010162-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001044242-A9 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001044242-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188524-A1 | Methods of treating pain | CDK3, CDK1, CDK5 | CDK2 4/4885CCNE2 84/4885CCNE1 137/4885 |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | NR5A1, CYP17A1, CYP21A2 | CDK2 2778/4885CCNE2 1200/4885CCNE1 1253/4885 |
| US-20030114504-A1 | Compositions and methods for the treatment of cancer | CDK4, CDK2, PLK1 | CDK2 2/4885CCNE2 414/4885CCNE1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.